ACKR3: A GPCR Implicated in Diabetes, Muscle Mass and Bone Development

Target Name: ACKR3

NCBI ID: G57007

ACKR3

ACKR3: A GPCR Implicated in Diabetes, Muscle Mass and Bone Development

G protein-coupled receptors (GPCRs) are a family of transmembrane proteins that play a crucial role in cellular signaling. GPCRs are involved in various physiological processes, including sensory perception, neurotransmission, and hormone signaling. The GPCR family consists of 尾2 subfamily, G伪, G尾, G纬, G未, G蔚, G蠁, G胃, GWi, and GZ伪 subfamilies. GPCRs are characterized by the presence of a transmembrane domain, a catalytic domain, and an extracellular region (ECR).

ACKR3 is a GPCR that is part of the G尾 subfamily. It is a 120 amino acid protein that is expressed in various tissues, including brain, heart, and pancreas.ACKR3 is involved in insulin signaling and has been implicated in the development and progression of type 2 diabetes.

ACKR3 is a potential drug target because of its role in insulin signaling. Insulin is a hormone that plays a crucial role in regulating blood sugar levels. It is produced by the pancreas and helps to lower blood sugar levels by allowing glucose to enter the cells where it is needed. However, insulin signaling is also affected by various factors, including obesity, physical inactivity, and an unhealthy diet.

ACKR3 is involved in the regulation of insulin sensitivity and has been shown to play a negative role in the development of type 2 diabetes. Studies have shown that individuals with a genetic variation in the ACKR3 gene are more likely to develop type 2 diabetes compared to individuals without the variation. Additionally, individuals with a higher BMI (body mass index) are also more likely to develop type 2 diabetes, which is associated with a decreased ACKR3 expression.

ACKR3 is also involved in the regulation of muscle mass and strength. muscle mass and strength are important for maintaining physical activity and overall health and are regulated by various hormones, including insulin.ACKR3 is known to be involved in the regulation of muscle mass and strength and has been shown to play a positive role in this process.

ACKR3 is also involved in the regulation of bone density and has been shown to play a negative role in the development of osteoporosis. Bone density is important for maintaining bone health and is regulated by various hormones, including insulin.ACKR3 is known to be involved in the regulation of bone density and has been shown to contribute to the development of osteoporosis.

ACKR3 is also involved in the regulation of insulin sensitivity and has been shown to play a negative role in the development of type 2 diabetes. Insulin sensitivity is important for maintaining healthy blood sugar levels and is regulated by various hormones, including insulin.ACKR3 is known to be involved in the regulation of insulin sensitivity and has been shown to contribute to the development of type 2 diabetes.

ACKR3 is also involved in the regulation of inflammation and has been shown to play a negative role in the development of various diseases, including heart disease and cancer. Inflammation is a natural response of the immune system, but chronic inflammation can contribute to the development of various diseases.ACKR3 is known to be involved in the regulation of inflammation and has been shown to contribute to the development of these diseases.

ACKR3 is also involved in the regulation of stem cell proliferation and has been shown to play a positive role in the development of stem cells. Stem cells are important for the development and maintenance of tissues and organs and are regulated by various hormones, including insulin.ACKR3 is known to be involved in the regulation of stem cell proliferation and has been shown to contribute to

Protein Name: Atypical Chemokine Receptor 3

Functions: Atypical chemokine receptor that controls chemokine levels and localization via high-affinity chemokine binding that is uncoupled from classic ligand-driven signal transduction cascades, resulting instead in chemokine sequestration, degradation, or transcytosis. Also known as interceptor (internalizing receptor) or chemokine-scavenging receptor or chemokine decoy receptor. Acts as a receptor for chemokines CXCL11 and CXCL12/SDF1 (PubMed:16107333, PubMed:19255243, PubMed:19380869, PubMed:20161793, PubMed:22300987). Chemokine binding does not activate G-protein-mediated signal transduction but instead induces beta-arrestin recruitment, leading to ligand internalization and activation of MAPK signaling pathway (PubMed:16940167, PubMed:18653785, PubMed:20018651). Required for regulation of CXCR4 protein levels in migrating interneurons, thereby adapting their chemokine responsiveness (PubMed:16940167, PubMed:18653785). In glioma cells, transduces signals via MEK/ERK pathway, mediating resistance to apoptosis. Promotes cell growth and survival (PubMed:16940167, PubMed:20388803). Not involved in cell migration, adhesion or proliferation of normal hematopoietic progenitors but activated by CXCL11 in malignant hemapoietic cells, leading to phosphorylation of ERK1/2 (MAPK3/MAPK1) and enhanced cell adhesion and migration (PubMed:17804806, PubMed:18653785, PubMed:19641136, PubMed:20887389). Plays a regulatory role in CXCR4-mediated activation of cell surface integrins by CXCL12 (PubMed:18653785). Required for heart valve development (PubMed:17804806). Regulates axon guidance in the oculomotor system through the regulation of CXCL12 levels (PubMed:31211835)

The "ACKR3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ACKR3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets